The Top 5 Biosimilar Articles for the Week of December 9

Number 5: Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.

Number 4: The FDA has approved Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara (ustekinumab) for the treatment of inflammatory bowel disease, plaque psoriasis, and psoriatic arthritis.

Number 3: A French real-world study found that the adalimumab biosimilar SB5 was effective in treating rheumatic or gastrointestinal immune-mediated inflammatory diseases, showing no loss of disease control in switched patients and similar persistence rates between naive and switched groups.

Number 2: Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.

Number 1: Biosimilars have gained success in recent years, with increased payer preference and market share, leading to significant price reductions and evidence of a competitive market from 2017 to 2022, according to a recent study.

To read all of these articles and more, visit centerforbiosimilars.com.